Candel Therapeutics Stock Performance

CADL Stock  USD 8.98  0.38  4.42%   
Candel Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.07, which signifies a somewhat significant risk relative to the market. Candel Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Candel Therapeutics is expected to follow. Use Candel Therapeutics total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to analyze future returns on Candel Therapeutics.

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
4.36
Five Day Return
(21.75)
Year To Date Return
(0.17)
Ten Year Return
28.21
All Time Return
28.21
1
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.46 subject to Rule 16b-3
12/04/2024
2
Disposition of 1800 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.85 subject to Rule 16b-3
12/06/2024
3
Acquisition by Benz Edward J. Jr of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3
12/10/2024
4
Disposition of 200000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 10.04 subject to Rule 16b-3
12/12/2024
5
Paul B. Manning Buys 1,250,000 Shares of Candel Therapeutics, Inc. Stock
12/20/2024
6
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.52 subject to Rule 16b-3
12/23/2024
7
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.82 subject to Rule 16b-3
12/24/2024
8
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 9.01 subject to Rule 16b-3
12/26/2024
9
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.85 subject to Rule 16b-3
12/27/2024
10
Disposition of 9884 shares by Charles Schoch of Candel Therapeutics at 6.4726 subject to Rule 16b-3
01/03/2025
11
Institutions profited after Candel Therapeutics, Inc.s market cap rose US41m last week but retail investors profited the most
01/06/2025
12
Acquisition by Nguyen Diem of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3
01/07/2025
13
Candel therapeutics CMO sells 88,749 in stock - Investing.com
01/10/2025
14
Disposition of 10428 shares by Nichols William Garrett of Candel Therapeutics at 7.225 subject to Rule 16b-3
01/15/2025
15
FMR LLCs Strategic Acquisition of Candel Therapeutics Shares
02/07/2025
16
Disposition of 31335 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.61 subject to Rule 16b-3
02/10/2025
17
Acquisition by Barone Francesca of 115000 shares of Candel Therapeutics at 8.55 subject to Rule 16b-3
02/12/2025
18
Trend Tracker for - Stock Traders Daily
02/13/2025
19
Major Indexes Falter Dow Drops Over 550 Points
02/20/2025
20
Disposition of 10582 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to Rule 16b-3
02/21/2025
21
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ...
02/25/2025
Begin Period Cash Flow70.3 M
  

Candel Therapeutics Relative Risk vs. Return Landscape

If you would invest  457.00  in Candel Therapeutics on December 2, 2024 and sell it today you would earn a total of  441.00  from holding Candel Therapeutics or generate 96.5% return on investment over 90 days. Candel Therapeutics is currently generating 1.902% in daily expected returns and assumes 13.7362% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Candel, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Candel Therapeutics is expected to generate 18.46 times more return on investment than the market. However, the company is 18.46 times more volatile than its market benchmark. It trades about 0.14 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.04 per unit of risk.

Candel Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Candel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Candel Therapeutics, and traders can use it to determine the average amount a Candel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1385

Best PortfolioBest Equity
Good Returns
Average ReturnsCADL
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 13.74
  actual daily
96
96% of assets are less volatile

Expected Return

 1.9
  actual daily
37
63% of assets have higher returns

Risk-Adjusted Return

 0.14
  actual daily
10
90% of assets perform better
Based on monthly moving average Candel Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Candel Therapeutics by adding it to a well-diversified portfolio.

Candel Therapeutics Fundamentals Growth

Candel Stock prices reflect investors' perceptions of the future prospects and financial health of Candel Therapeutics, and Candel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Candel Stock performance.

About Candel Therapeutics Performance

By examining Candel Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Candel Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Candel Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.06)(1.01)
Return On Capital Employed(1.63)(1.55)
Return On Assets(1.06)(1.01)
Return On Equity(3.42)(3.25)

Things to note about Candel Therapeutics performance evaluation

Checking the ongoing alerts about Candel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Candel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Candel Therapeutics is way too risky over 90 days horizon
Candel Therapeutics appears to be risky and price may revert if volatility continues
Candel Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M).
Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0.
Roughly 30.0% of the company shares are held by company insiders
Latest headline from gurufocus.com: Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ...
Evaluating Candel Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Candel Therapeutics' stock performance include:
  • Analyzing Candel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Candel Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Candel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Candel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Candel Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Candel Therapeutics' stock. These opinions can provide insight into Candel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Candel Therapeutics' stock performance is not an exact science, and many factors can impact Candel Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.